Clinical Improvement

Citalopram-induced pathways regulation and tentative treatment-outcome-predicting biomarkers in lymphoblastoid cell lines from depression patients | 7/1/2020

… status under all incubation conditions ( p  = 0.014–0.021) while GAD1 showed marginal to significant association with response status ( p  = 0.038–0.069, Supplementary Table 9 ). Pearson’s analyses showed significant correlations between NFIB expression (∆Cp) and clinical improvement ( p  = 0.015–0.025, r  = −0.123 to −0.295, Supplementary Table 10 ). In addition to the bivariate statistics, clinical response and remission were tested for effects on gene expression in a linear mixed-effects (LME) model …

What Is the Survivorship After Hip Arthroscopy for Femoroacetabular Impingement? A Large-database Study | 7/1/2020

… Arthroscopy for Femoroacetabular Impingement? A Large-database… What Is the Survivorship After Hip Arthroscopy for Femoroacetabular Impingement? A Large-database Study July 1, 2020 Print Background: Patients with femoroacetabular impingement (FAI) may experience lasting clinical improvement after hip arthroscopy; however, some patients will still eventually undergo early conversion to THA due to unresolved symptoms and progression of arthritis. However, the risk of this has been only incompletely characterized in prior …

Follow Clinical Improvement:    

Coronavirus tracker: U.S. calls dibs on remdesivir supplies; Sinopharm doubles shot capacity with new Wuhan plant | FiercePharma | 7/1/2020

… phase 3 Simple trial for remdesivir in COVID-19 patients with pneumonia, but without reduced oxygen levels. Patients who took a 5-day course of remdesivir were 65% more likely to show signs of clinical improvement compared with patients who received standard care, the company said. Story Could COVID-19 be a vascular disease? The Lancet explored the idea in a three-patient analysis that found traces of the virus …

COVID-19 Treatments — Coronavirus Today | 6/30/2020

… in 230 patients with SARS-CoV-2 infections. June 3, 2020 - Among patients with severe or life-threatening COVID-19, convalescent plasma therapy added to standard treatment did not significantly improve the time to clinical improvement within 28 days, although the trial was terminated early and may have been underpowered to detect a clinically important difference, reported a study published by JAMA. June 1, 2020 - Eli Lilly announced patients have …

Bulls Take Charge of Humanigen Inc (OTCMKTS: HGEN) | 6/30/2020

… storms, according to a study from scientists at the Mayo Clinic. The Phase 3 trial is ongoing. On June 15 the Company announced data on the first clinical use of lenzilumab. Patients showed rapid clinical improvement with a median time to recovery of five days, median time to discharge of five days and 100% survival to the data cut-off date. Humanigen Inc (OTCMKTS: HGEN) is a clinical stage biopharmaceutical …

3 “Strong Buy” Coronavirus Stocks With Massive Upside Potential | Yahoo News | 6/29/2020

… new data released from an open-label, single-active arm, single center study in Italy in non-mechanically ventilated patients with severe COVID-19 pneumonia and hyperinflammation, patients given KNSA’s candidate saw a significant clinical improvement . Highlighting the details of the study, JMP analyst Liisa Bayko pointed out that each patient was given medical treatment hydroxychloroquine, azithromycin and lopinavir/ritonavir as well as respiratory support with supplemental oxygen and/or …

EXELDERM (sulconazole nitrate) solution [Sun Pharmaceutical Industries, Inc.] | National Institutes of Health | 6/29/2020

… the solution should be gently massaged into the affected and surrounding skin areas once or twice daily. Symptomatic relief usually occurs within a few days after starting EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0%, and clinical improvement usually occurs within one week. To reduce the possibility of recurrence, tinea cruris, tinea corporis, and tinea versicolor should be treated for 3 weeks. If significant clinical improvement is not seen after 4 weeks …

PREDNISOLONE SODIUM PHOSPHATE ODT (prednisolone sodium phosphate) tablet, orally disintegrating PREDNISOLONE SODIUM PHOSPHATE tablet, orally disintegrating [Prasco Laboratories] | National Institutes of Health | 6/29/2020

… or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevation of creatinine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years. 5.12 Kaposi’s Sarcoma Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may …

Report describes intoxication with new psychoactive substance | 6/27/2020

… and slurred speech were the most common clinical findings. Nick Matthews/CC BY-SA 2.0 One student had mild respiratory depression with a respiratory rate of 10 breaths per minute. “All patients had sufficient clinical improvement within 6 hours such that they could be discharged from the hospital,” according to a description of the cases that was published online in Pediatrics . The report is the first to detail clinical toxicity …

Treating Corona: 3 successful plasma therapies shows ray of hope | 6/27/2020

… Minister, Government of Rajasthan . After working day & night on a war-footing level in a bid to save lives, three successful Convalescent Plasma Therapies have been conducted and all the three patients have shown clinical improvement . Dr Bhandari said, “So far, we have conducted 3 successful COVID Plasma therapies and all the 3 patients are showing improvement in their clinical state, oxygen saturation and d-dimer levels. We have included …

Performance Status Is a Predictive Factor of Improvement after Colonic Stenting in Patients with Malignant Stenosis due to Extraparenteral Malignant Tumors | 6/27/2020

… malignant tumors (EPMTs). However, predictive factors for improving clinical outcomes after colonic stenting for EPMTs remain unclear. This study is aimed at evaluating patients with EPMTs who underwent colonic stenting and investigating factors influencing clinical improvement after the stenting procedure. Twenty-one patients with colorectal obstruction by EPMTs were treated using self-expandable metallic stents over a period of 8 years. We divided the enrolled patients into the clinically improved …

Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review | BMJ | 6/26/2020

… Twenty-six RCTs examined the impact of treatment on SF-36 results. Several examples are summarised in this section. Results from two of three trials that evaluated abetimus sodium indicated that SF-36 reflected clinical improvement s in SLE accompanied by improvements ≥MCID in SF-36. 31–33 Furie et al 34 studied the safety and efficacy of belimumab 1 mg/kg and 10 mg/kg in patients with SLE and …

FiercePharmaAsia—WuXi NextCODE rebrand; remdesivir generic prices; Sinopharm COVID vax phase 3 | 6/26/2020

… release, PDF) India’s Glenmark Pharmaceuticals has won local approval for a generic version of Fujifilm’s flu drug Avigan (favipiravir) for mild to moderate COVID-19. According to Glenmark, the drug delivered up to 88% clinical improvement in mild to moderate COVID-19 cases, with rapid reduction in viral load in four days. Read more on …

Effects of combining constraint-induced movement therapy and action-observation training on upper limb kinematics in children with unilateral cerebral palsy: a randomized controlled trial | FiercePharma | 6/26/2020

… set at 0.05, and Bonferroni-corrected for post-hoc analysis (division by the number of comparisons (i.e. 0.05/3)). Finally, to evaluate whether there was an association between the improvements in motor control parameters and clinical improvement , we ran correlation analyses between the change of these variables using Spearman correlations, due to the ordinal characteristics of the clinical measures. We ran the correlation analyses for change between T1-T2 and between …

The smart Trick of nearest colorado dispensary That No One is Discussing | 6/25/2020

The smart Trick of nearest colorado dispensary That No One is Discussing The smart Trick of nearest colorado dispensary That No One is Discussing Category: Blog The Clinical Improvement phase is made up of clinical research of latest and existing shipping systems and gadgets that have the possible to deliver safe, efficient and measured doses of medical cannabis to clients. The Expenditure Entity section measures and evaluates the overall performance …

Roundup: GE Healthcare launches AI suite to detect COVID-19 abnormalities, Health Help Now app to close and more briefs | Healthcare IT News | 6/25/2020

… in disorders and anxieties linked to the pandemic and emerging as the lockdown continues to ease. The research highlights how digital cognitive behavioural therapy (iCBT) as part of wider psychological care can deliver strong clinical improvement s and recovery. Psychiatric interviews of participants at three months after treatment found that, overall, 56.4% no longer had a diagnosis of anxiety and/or depression. A further decrease in symptom scores was seen after …

PREDNISONE tablet PREDNISONE solution PREDNISONE INTENSOL solution, concentrate [Hikma Pharmaceuticals USA Inc.] | National Institutes of Health | 6/25/2020

… and as to whether daily or intermittent therapy should be used. Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement . Cardio-Renal As sodium retention with resultant edema and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency …

METHOTREXATE tablet [PD-Rx Pharmaceuticals, Inc.] | National Institutes of Health | 6/25/2020

… 4 to 6 weeks. Methotrexate in combination with other agents appears to be the drug of choice for securing maintenance of drug-induced remissions. When remission is achieved and supportive care has produced general clinical improvement , maintenance therapy is initiated, as follows: Methotrexate is administered 2 times weekly either by mouth or intramuscularly in total weekly doses of 30 mg/m 2 . It has also been given in doses of …

KENALOG-10 (triamcinolone acetonide) injection, suspension [E.R. Squibb & Sons, L.L.C.] | National Institutes of Health | 6/25/2020

… and as to whether daily or intermittent therapy should be used. Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement . Cardio-Renal As sodium retention with resultant edema and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency …

Early Data on Remdesivir for Severe COVID-19: A Promising Start? | 6/25/2020

In this group of patients hospitalized with severe COVID-19, most of whom required invasive ventilation, 68% showed clinical improvement after treatment with remdesivir on a compassionate-use basis. SOURCE : Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med 2020; April 10. doi: 10.1056/NEJMoa2007016. [Online ahead of print]. C OVID-19 has overwhelmed health systems globally …

Publication of Data from Severe COVID-19 Patients Shows Substantial Benefit to Patients Treated with RedHill’s Opaganib Compared to Matched Case-Control Group Tel Aviv Stock Exchange:RDHL.TA | Globe Newswire | 6/24/2020

… are only preliminary, are based on clinical results of a very limited number of patients and are not part of a clinical study. There is no guarantee that these patients will continue to show clinical improvement or that other patients will show similar clinical improvement . Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the …

Rasmussen’s Encephalitis: A Report of a Tunisian Pediatric Case and Literature Review | 6/24/2020

… received a pulse of steroids (1 g/day) during 5 days and, then, relay per os at the dose of 1 mg/kg/day for 10 days. Valproic acid and clobazam were prescribed with clinical improvement and partial seizure control. A second brain MRI performed after 3 weeks was normal. On April 2015, he presented with intractable focal right seizures, progressive impairment of language abilities, and behavioral disorders with irritability …

Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization | 6/23/2020

Binding IgG detected by ELISA 2 COVID-19 patients Reduced sputum viral load Radiological and clinical improvement s No adverse effects observed Assays are now available for detecting IgA, IgM, and IgG specific for SARS-CoV-2 in patient serum, that is to demonstrate seroconversion, and also for detecting NAbs ( Amanat et al., 2020 ; Wu et al., 2020 ). These techniques are rapidly evolving, and additional information on the antibody response to …

A Secret Weapon For gunpo massage | 6/23/2020

A Secret Weapon For gunpo massage 블랙홀출장정보 - 출장마사지정보.블랙홀.홈케어.홈타이.타이.아로마.출장샵In the course of the 1930s and 1940s massage’s affect decreased due to clinical improvement s of some time, although in the seventies massage’s affect grew once again that has a noteworthy rise amid athletes.[ten] Till the 1970s, nurses utilised massage to reduce ache and assist slumber.Burmese massage is a complete body massage approach that commences from head to toes, drawing on …

Fabi Flu Glenmark: 5 Points About the Drug Approved for COVID-19 Treatment in India - blogingbuddy | 6/23/2020

… administered to 150 COVID-19 patients with mild to moderate illness. The drug was used to treat the patients for 14 days, but the study lasted for a month and concluded that Favipiravir showed clinical improvement s by about 88% in the patients. The study itself is yet to be published in a peer-reviewed journal. Favipiravir was the frontrunner among the 25 repurposed drugs the Council of Scientific and Industrial …

COVID-19

Coronavirus tracker: U.S. calls dibs on remdesivir supplies; Sinopharm doubles shot capacity with new Wuhan plant | FiercePharma | 7/1/2020

Fujifilm has partnered up with Indian drugmaker Dr. Reddy’s to sell doses of the flu med Avigan for COVID-19 treatment around the world; the drug is still locked in clinical trials in its native … of remdesivir were 65% more likely to show signs of clinical improvement compared with patients who received standard care, the company said. Story Could COVID-19 be a vascular disease? The Lancet explored the idea …

Biopharma

RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK | Globe Newswire | 6/29/2020

… severe COVID-19 patients has been initiated at leading medical centers TEL-AVIV, Israel and RALEIGH, N.C., June 29, RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that … COVID-19 patients treated with opaganib will not show any clinical improvement; the risk that clinical trials of opaganib in Israel, the U.S., Italy, Russia, the UK or elsewhere for the treatment of COVID-19 …

Food and Drug Administration

Roundup: GE Healthcare launches AI suite to detect COVID-19 abnormalities, Health Help Now app to close and more briefs | Healthcare IT News | 6/25/2020

… Mark enables Akili to market EndeavorRx in European Economic Area (EEA) member countries. The CE Mark follows last week’s US Food and Drug Administration (FDA) decision, which made EndeavorRx the first FDA-cleared prescription treatment … iCBT) as part of wider psychological care can deliver strong clinical improvements and recovery. Psychiatric interviews of participants at three months after treatment found that, overall, 56.4% no longer had a diagnosis of anxiety and …

National Institute of Allergy and Infectious Diseases

Gilead hopes to start inhaled remdesivir trial in healthy volunteers in August - MedCity News | 6/22/2020

… National Institute of Allergy and Infectious Diseases. The data showed that patients who received remdesivir recovered four days faster – within 11 days – than those in the placebo group. Most recently, data from a Phase III study run by Gilead showed that a greater percentage of patients with moderate Covid-19 pneumonia who received the drug over five days showed a benefit on a scale of clinical improvement than did those …

Biotech

Race For Vaccine Intensifies As COVID-19 Second Wave of Outbreaks Threatens | PR Newswire | 6/17/2020

… drug companies, government laboratories and top universities — are working on a vaccine or other treatments, according to leading researchers.” Active biotech companies with recent developments include: Nascent Biotech, Inc. (OTCQB: NBIO ), Moderna, Inc. (NASDAQ: MRNA … remdesivir treatment group were 65 percent more likely to have clinical improvement at Day 11 compared with those in the standard of care group (OR 1.65 [95% CI 1.09-2.48]; p=0.017). The odds of improvement …

National Institutes of Health

A drug from Shkreli’s former company Humanigen shows early promise in COVID-19 | FierceBiotech | 6/17/2020

… with an FDA emergency authorization in COVID-19—as posted in a separate placebo-controlled clinical trial conducted by the National Institutes of Health. Encouraged by the early results, Humanigen has launched a phase 3 … investigational drug outside a clinical trial, lenzilumab led to rapid clinical improvement. Of the 12 patients who received lenzilumab, 11 were already discharged at the data cutoff date. The treatment also produced a significant improvement …

NIH

Eli Lilly, spurred by AI analysis, starts pivotal study of arthritis med Olumiant in COVID-19 | FiercePharma | 6/15/2020

… hospitalized patients, it said Monday. Data from the trial, expected in the next few months, will complement those from the NIH-run ACTT-2 trial, which is combining Olumiant with Gilead Sciences’ remdesivir. The drug … Olumiant and placebo. Investigators will also measure other outcomes, including clinical improvement, time to recovery and duration of hospitalization. Besides Olumiant, Lilly is working on two investigational neutralizing antibody drugs specifically designed to target the …

Institutional Review Board

OncoImmune, Inc. Reports Progress on its Phase III Clinical Trial testing CD24Fc for Severe and Critical COVID-19 | Business Wire | 6/14/2020

… randomized and received either CD24Fc or placebo as the treatment for severe COVID-19. After reviewing the safety data, the Institutional Review Board has approved continuing enrollment while interim analysis occurs. Current therapeutic strategies for … up for 28 days thereafter to determine the time to clinical improvement. Because the drug works through a novel mechanism that does not duplicate that of other experimental therapeutics, patients enrolled in other trials need …

Coronavirus

CytoDyn Reached Its Enrollment Target for Phase 2 COVID-19 Trial for Mild to Moderate Indication – Primary End Point Announcement Is Next | Globe Newswire | 6/11/2020

… Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19.” This Phase 2 trial evaluates clinical improvement of several symptoms over a 14-day period, including changes in multiple clinical … have these important results in 2 to 3 weeks.” About Coronavirus Disease 2019 CytoDyn has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical trial for …

Medicaid

VasQ™ External Support Awarded Breakthrough Device Designation by the FDA | PR Newswire | 6/8/2020

Medicaid Services as substantiation of clinical improvement in their consideration for providing additional reimbursement for new technologies. The designation was based in part on the breadth of clinical evidence collected so far for VasQ that consistently demonstrates improvement over the standard of care for creating functional AVFs for hemodialysis treatment. AVFs are the preferred option by physicians for hemodialysis patients to enable effective treatment because of their long-term benefits …

Medicare

VasQ™ External Support Awarded Breakthrough Device Designation by the FDA | PR Newswire | 6/8/2020

Medicare and Medicaid Services as substantiation of clinical improvement in their consideration for providing additional reimbursement for new technologies. The designation was based in part on the breadth of clinical evidence collected so far for VasQ that consistently demonstrates improvement over the standard of care for creating functional AVFs for hemodialysis treatment. AVFs are the preferred option by physicians for hemodialysis patients to enable effective treatment because of their long …

Centers for Medicare and Medicaid Services

VasQ™ External Support Awarded Breakthrough Device Designation by the FDA | PR Newswire | 6/8/2020

Centers for Medicare and Medicaid Services as substantiation of clinical improvement in their consideration for providing additional reimbursement for new technologies. The designation was based in part on the breadth of clinical evidence collected so far for VasQ that consistently demonstrates improvement over the standard of care for creating functional AVFs for hemodialysis treatment. AVFs are the preferred option by physicians for hemodialysis patients to enable effective treatment because of …

Genomics

Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology | Globe Newswire | 5/26/2020

… this rare condition,” said George Diaz, M.D., Ph.D., division chief of medical genetics in the Division of Medical Genetics and Genomics and Department of Genetics and Genomic Sciences at the Icahn School of Medicine at … extension data for pegzilarginase in patients with ARG1-D demonstrated clinical improvements and sustained lowering of plasma arginine. The Company’s single, global pivotal Phase 3 PEACE trial is designed to assess the effects of treatment …

Home Health

AMC Health Expands Partnership with Gallagher Home Health Services to Utilize Telehealth Monitoring Solutions to Help Assess, Monitor and Triage COVID Patients At-Home | PR Newswire | 5/4/2020

AMC Health Expands Partnership with Gallagher Home Health Services to Utilize Telehealth Monitoring Solutions to Help Assess, Monitor and Triage COVID Patients At-Home News provided by May 04, 2020, 08:39 ET Share this article … a single connection. AMC Health’s peer-reviewed published studies highlight clinical improvements for conditions like heart failure, diabetes, COPD and hypertension, resulting in reductions in hospital admissions, and solid financial return on investment. For more …

CDC

AbbVie’s HIV drug fails Covid-19 trial in China, but a Fujifilm flu drug may have efficacy - MedCity News | 3/20/2020

This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses Researchers in China testing drugs as potential treatments for Covid-19 racked up one failure and one … from the standard of care in terms of time to clinical improvement. Thirteen patients receiving the drug dropped out due to adverse events, but although gastrointestinal side effects were higher in the Kaletra group, serious …

Patient Satisfaction

Keep patients in focus with a digital population health solution — 4 technology pillars and 3 steps for success | Becker’s Hospital Review | 12/3/2019

… clinical improvement, financial or contract goals, or patient satisfaction. “The fact of the matter is, it’s never about one of these — it’s about all of them, or some combination thereof, so you need to know what you want to measure and what the data source is, and bring that information from multiple places to save money and time,” Dr. Blackman said. 2. Identify needs: With a strategy fully defined and …

Telehealth

Keep patients in focus with a digital population health solution — 4 technology pillars and 3 steps for success | Becker’s Hospital Review | 12/3/2019

… first and most important step is deploying and defining a strategy: determining whether the goals of the software lie in clinical improvement, financial or contract goals, or patient satisfaction. “The fact of the matter is … in care, think beyond the in-person visit to encompass telehealth and other virtual solutions, address the patients not currently being seen, and feature a robust analytics strategy to create insights and enable action. “A …

Population Health

Keep patients in focus with a digital population health solution — 4 technology pillars and 3 steps for success | Becker’s Hospital Review | 12/3/2019

In the U.S. the push for population health management is largely driven by rising healthcare costs and rates of chronic illness. Costs are growing at an unsustainable rate and do not correspond with care quality … strategy: determining whether the goals of the software lie in clinical improvement, financial or contract goals, or patient satisfaction. “The fact of the matter is, it’s never about one of these — it’s about all of …

Health Management

Keep patients in focus with a digital population health solution — 4 technology pillars and 3 steps for success | Becker’s Hospital Review | 12/3/2019

In the U.S. the push for population health management is largely driven by rising healthcare costs and rates of chronic illness. Costs are growing at an unsustainable rate and do not correspond with care quality … strategy: determining whether the goals of the software lie in clinical improvement, financial or contract goals, or patient satisfaction. “The fact of the matter is, it’s never about one of these — it’s about all of …

Clinical Pharmacology

METHOTREXATE injection, solution [Teva Parenteral Medicines, Inc.] | National Institutes of Health | 12/3/2019

… mL solutions contain approximately 0.43 mEq, 2.15 mEq and 8.60 mEq of sodium per vial, respectively, and are isotonic solutions. CLINICAL PHARMACOLOGY Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this … Limited data from long-term studies indicate that an initial clinical improvement is maintained for at least two years with continued therapy. In psoriasis, the rate of production of epithelial cells in the skin is …

Smoking Cessation

PREDNISONE tablet [A-S Medication Solutions] | National Institutes of Health | 12/2/2019

… been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement. Cardio-Renal As sodium retention with resultant edema and potassium loss may occur … Lifestyle modification to reduce the risk of osteoporosis (e.g., cigarette smoking cessation, limitation of alcohol consumption, participation in weight-bearing exercise for 30 to 60 minutes daily) should be encouraged. Calcium and vitamin D supplementation …

Gene Therapy

UMass Med School gene therapy shows promising early results in tackling Tay-Sachs - News - telegram.com - Worcester, MA | 11/28/2019

UMass Med School gene therapy shows promising early results in tackling Tay-Sachs Susan Spencer Telegram & Gazette Staff @SusanSpencerTG Wednesday Nov 27, 2019 at 6:11 PM Nov 27, 2019 at 6:37 PM WORCESTER — The fight … injected into fluid surrounding the brain. The patient hasn’t shown clinical improvement in functioning but biochemical changes were detected in the brain, indicating partial re-creation of the missing enzyme associated with Tay-Sachs, Flotte …

Patient Safety

(USA-MA-Boston) Director, Patient Safety | 11/27/2019

Job Information Dana-Farber Cancer Institute Director, Patient Safety in Boston , Massachusetts The Director of patient Safety is responsible leading, evaluating, and implementing patient safety and clinical improvement initiatives across the Dana-Farber Cancer Institute (DFCI) continuum. The incumbent is responsible for Infection Control in collaboration with the Hospital Epidemiologist across DFCI. The [job title] is responsible for ensuring visibility of patient safety programs across DFCI and leading a non …

Clinical Decision Support

GE Healthcare introduces Edison Developer Program to spur AI advancements | Healthcare IT News | 11/27/2019

… for its Edison platform, the program will offer services meant to help developers to build better models for operational and clinical improvements. November 27, 2019 02:04 PM With its new Edison Developer Program, GE Healthcare … and Volpara – aimed at imaging workflows for CTs and MRIs, clinical decision support and more. Officials say the Edison Developer Program offers new potentials for innovating secure device connectivity, data aggregation for clinical context, advanced …

Infection Control

(USA-MA-Boston) Director, Patient Safety | 11/27/2019

Job Information Dana-Farber Cancer Institute Director, Patient Safety in Boston , Massachusetts The Director of patient Safety is responsible leading, evaluating, and implementing patient safety and clinical improvement initiatives across the Dana-Farber Cancer Institute (DFCI) continuum. The incumbent is responsible for Infection Control in collaboration with the Hospital Epidemiologist across DFCI. The [job title] is responsible for ensuring visibility of patient safety programs across DFCI and leading a non …

Novartis

Coronavirus tracker: U.S. calls dibs on remdesivir supplies; Sinopharm doubles shot capacity with new Wuhan plant | FiercePharma | 7/1/2020

… called dibs on the its next 500,000 doses, shutting out other countries for at least the next three months. Plus, Novartis CEO Vas Narasimhan sat down with Wired to talk vaccines, pricing and drug launches … of remdesivir were 65% more likely to show signs of clinical improvement compared with patients who received standard care, the company said. Story Could COVID-19 be a vascular disease? The Lancet explored the idea …

Gilead

Coronavirus tracker: U.S. calls dibs on remdesivir supplies; Sinopharm doubles shot capacity with new Wuhan plant | FiercePharma | 7/1/2020

… Wuhan, driving up capacity to more than 200 million doses per year. Meanwhile, the U.S. bought out the bulk of Gilead’s remdesivir supply for the next three months, leaving other countries wanting. GlobalData revealed that … of remdesivir were 65% more likely to show signs of clinical improvement compared with patients who received standard care, the company said. Story Could COVID-19 be a vascular disease? The Lancet explored the idea …

Gilead Sciences

Coronavirus tracker: U.S. calls dibs on remdesivir supplies; Sinopharm doubles shot capacity with new Wuhan plant | FiercePharma | 7/1/2020

… later this year. In a move condemned for putting “America first” amid the pandemic, the U.S. has reportedly bought out Gilead Sciences’ entire remdesivir supply for July, and the lion’s share for the next two … of remdesivir were 65% more likely to show signs of clinical improvement compared with patients who received standard care, the company said. Story Could COVID-19 be a vascular disease? The Lancet explored the idea …

Regeneron Pharmaceuticals

Gilead hopes to start inhaled remdesivir trial in healthy volunteers in August - MedCity News | 6/22/2020

… patients with moderate Covid-19 pneumonia who received the drug over five days showed a benefit on a scale of clinical improvement than did those who received the drug for 10 days. But because the … symptoms, as well as direct-acting antivirals. Earlier this month, Regeneron Pharmaceuticals started clinical development of a cocktail treatment of two monoclonal antibodies developed specifically for the SARS-CoV-2 virus, while PTC Therapeutics plans …

Incyte

Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients | Globe Newswire | 6/18/2020

… randomized, double-blind, placebo‑controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, in hospitalized adults with COVID-19. Baricitinib, marketed as OLUMIANT ® , is approved in 70 … outcomes of this study include the proportion of patients with clinical improvement at different time points, time to recovery, duration of hospitalization, number of ventilator-free days and mortality over a 28-day period. “Lilly …

Johnson & Johnson

Ankylosing Spondylitis Market Size Worth $7.9 Billion By 2027 | CAGR: 8.3%: Grand View Research, Inc. | PR Newswire | 6/18/2020

… Pharmaceutical companies are aiming at label expansion and patent extension for maintaining their share in the market. In October 2017 , Johnson & Johnson Services received approval for Simponi Aria for AS treatment for the treatment active … approximately 20 to 40% of patients fail to achieve sufficient clinical improvement on anti-TNF drugs, which provides opportunities for companies to develop novel and effective drugs. Grand View Research has segmented the global ankylosing …

Inovio Pharmaceuticals

Race For Vaccine Intensifies As COVID-19 Second Wave of Outbreaks Threatens | PR Newswire | 6/17/2020

… biotech companies with recent developments include: Nascent Biotech, Inc. (OTCQB: NBIO ), Moderna, Inc. (NASDAQ: MRNA ), Gilead Sciences, Inc. (NASDAQ: GILD ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), Eli Lilly and Company (NYSE: LLY ). The LA Time article … remdesivir treatment group were 65 percent more likely to have clinical improvement at Day 11 compared with those in the standard of care group (OR 1.65 [95% CI 1.09-2.48]; p=0.017). The odds of improvement …

Eli Lilly

Race For Vaccine Intensifies As COVID-19 Second Wave of Outbreaks Threatens | PR Newswire | 6/17/2020

… include: Nascent Biotech, Inc. (OTCQB: NBIO ), Moderna, Inc. (NASDAQ: MRNA ), Gilead Sciences, Inc. (NASDAQ: GILD ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), Eli Lilly and Company (NYSE: LLY ). The LA Time article continued : “No response has ever … remdesivir treatment group were 65 percent more likely to have clinical improvement at Day 11 compared with those in the standard of care group (OR 1.65 [95% CI 1.09-2.48]; p=0.017). The odds of improvement …

AstraZeneca

Dr. Reddy’s Inks Deal With Gilead Sciences for Remdesivir - June 15, 2020 - Zacks.com | 6/15/2020

clinical improvement at day 11 compared with those in the standard of care group. However, the odds of improvement in clinical status with the 10-day treatment course of remdesivir versus standard of care alone were favorable but did not attain statistical significance. Meanwhile, several marketed drugs like Sanofi,/Regeneron’s IL-6 inhibitor Kevzara, Roche’s ( RHHBY - Free Report ) IL-6 inhibitor, Actemra, Incyte/Novarts’ JAK1/JAK2 inhibitor, Jakafi, AstraZeneca’s ( AZN …

Genentech

Genentech Initiates Phase III Clinical Trial of Actemra Plus Remdesivir in Hospitalized Patients With Severe COVID-19 Pneumonia | Business Wire | 5/28/2020

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–May 28, 2020– Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the initiation of a global Phase III, randomized, double-blind, multicenter study … mortality, mechanical ventilation, clinical status at day 14, time to clinical improvement, and time to discharge. About Actemra Actemra was the first humanized interleukin-6 (IL-6) receptor antagonist approved for the treatment of adult …

AMC Health

AMC Health Expands Partnership with Gallagher Home Health Services to Utilize Telehealth Monitoring Solutions to Help Assess, Monitor and Triage COVID Patients At-Home | PR Newswire | 5/4/2020

AMC Health Expands Partnership with Gallagher Home Health Services to Utilize Telehealth Monitoring Solutions to Help Assess, Monitor and Triage COVID Patients At-Home News provided by May 04, 2020, 08:39 ET Share this article … a single connection. AMC Health’s peer-reviewed published studies highlight clinical improvements for conditions like heart failure, diabetes, COPD and hypertension, resulting in reductions in hospital admissions, and solid financial return on investment. For more …

BioCryst

BioCryst Begins Study on Galidesivir for Coronavirus Infection - April 13, 2020 - Zacks.com | 4/13/2020

BioCryst Pharmaceuticals, Inc. ( BCRX - Free Report ) announced that it has initiated enrollment in a clinical study on its pipeline candidate galidesivir for treating patients with the novel coronavirus disease (COVID-19). The double-blind, placebo … the COVID-19 study will include the time taken to clinical improvement, time to hospital discharge, time to undetectable levels as measured by polymerase chain reaction (PCR) in respiratory specimens of SARS-CoV-2. Per …

Biogen

FiercePharmaAsia—Biogen’s, Bayer’s rogue employees; Kaletra’s COVID-19 trial flop; BioNTech-Fosun deal | 3/20/2020

A former Biogen employee is under investigation in Beijing for allegedly concealing her COVID-19 symptoms and putting fellow travelers at risk of infection during a flight back to China. Bayer has fired an employee … failed to beat standard care at cutting the time to clinical improvement and the 28-day mortality rate. One analyst argues the med might be more helpful in less severe patients, though. 4. With weeks …

AbbVie

FiercePharmaAsia—Biogen’s, Bayer’s rogue employees; Kaletra’s COVID-19 trial flop; BioNTech-Fosun deal | 3/20/2020

… a 14-day quarantine rule in China after videos of the woman’s behavior went viral. A Chinese research team found AbbVie’s HIV combo Kaletra offered no benefits over standard care in severe COVID-19 patients … failed to beat standard care at cutting the time to clinical improvement and the 28-day mortality rate. One analyst argues the med might be more helpful in less severe patients, though. 4. With weeks …

Boston Scientific

Bioresorbable scaffold effectively treats below-the-knee lesions | 11/14/2019

… below-the-knee lesions, the patency rate was 11.6%, he said. In addition, he said, 95% of patients showed sustained clinical improvement at 35 months, dropping in Rutherford class. The study included 48 patients (mean … Disclosure s : Kum reports he has financial ties with Abbott, Boston Scientific and LimFlow. Varcoe reports he consulted for and/or received honoraria from Abbott Vascular, Boston Scientific, Intact Vascular, Medtronic, Shockwave Medical and Surmodics …

GlaxoSmithKline

Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights | Globe Newswire | 11/6/2019

… industry. Dr. Ravi Rao joined the Company as Chief Medical Officer in November 2019. Dr. Rao comes to Aeglea from GlaxoSmithKline, where he served as Vice President, Global Medical Affairs Head, Immunology and Specialty Franchise … data for pegzilarginase in patients with Arginase 1 Deficiency demonstrated clinical improvements and sustained lowering of plasma arginine. The Company’s single, global pivotal Phase 3 PEACE trial is designed to assess the effects of treatment …

Enable Healthcare

Leading Expert in Internal Medicine and Diabetes, Dr. Gregory Peterson, Joins AMC Health’s Clinical Leadership Team as Chief Medical Director to Enhance Remote Patient Monitoring (RPM) Solutions | PR Newswire | 10/30/2019

enable healthcare organizations to securely extend their services beyond the four walls of the hospital and ambulatory clinic settings. Providing cost-effective population health management, the company’s ever-expanding ecosystem delivers scalable virtual care programs for health systems and payers, connecting to more than 200 devices, apps, and integrations via a single connection. AMC Health’s peer-reviewed published studies highlight clinical improvements for conditions like heart failure, diabetes, and hypertension …

Zynx Health

(USA-CA-Los Angeles) Account Executive | 10/27/2019

… ZYNX HEALTH Zynx Health, a subsidiary of Hearst Corporation, is the market leader in providing evidence-based and experience-based clinical decision support solutions proven to measurably improve the quality, safety, and efficiency of patient care. Zynx Health provides clinical evidence, order sets, plans of care, actionable rules, and other forms of clinical decision support that drive clinical improvements at the point of care and aligns with healthcare industry drivers …

Hearst Health

New Zynx Health Tool Streamlines Data Extraction From Cerner EHRs | Health IT Outcomes | 10/1/2019

… by tightening integration with Knowledge Analyzer Los Angeles, CA /PRNewswire/ - Zynx Health ™, market leader in providing evidence- and experience-based clinical improvement solutions since 1996, announced today the release of Import Manager, a new tool … at zynxhealth.com . About Zynx Health Zynx Health, part of the Hearst Health network, provides healthcare professionals with vital information and processes that guide care decisions and reduce complexity across the entire patient journey in a …

First Databank

With Quality a Top Priority, Ardent Health Services Expands Its Use of Zynx Health’s Knowledge Analyzer | PR Newswire | 7/9/2019

LOS ANGELES Zynx Health ™, market leader in providing evidence- and experience-based clinical improvement solutions since 1996, announced today that long-time client Ardent Health Services is expanding its agreement for use of Zynx’s Knowledge … 3.2 billion dispensed prescriptions. The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase, MHK (formerly MedHOK—Medical House of Knowledge) and Hearst Health Ventures ( www.hearsthealth.com ). Hearst also holds a minority interest …

MedHOK

With Quality a Top Priority, Ardent Health Services Expands Its Use of Zynx Health’s Knowledge Analyzer | PR Newswire | 7/9/2019

LOS ANGELES Zynx Health ™, market leader in providing evidence- and experience-based clinical improvement solutions since 1996, announced today that long-time client Ardent Health Services is expanding its agreement for use of Zynx’s Knowledge … FDB (First Databank), Zynx Health, MCG, Homecare Homebase, MHK (formerly MedHOK—Medical House of Knowledge) and Hearst Health Ventures ( www.hearsthealth.com ). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen …

Homecare Homebase

With Quality a Top Priority, Ardent Health Services Expands Its Use of Zynx Health’s Knowledge Analyzer | PR Newswire | 7/9/2019

LOS ANGELES Zynx Health ™, market leader in providing evidence- and experience-based clinical improvement solutions since 1996, announced today that long-time client Ardent Health Services is expanding its agreement for use of Zynx’s Knowledge … Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase, MHK (formerly MedHOK—Medical House of Knowledge) and Hearst Health Ventures ( www.hearsthealth.com ). Hearst also holds a minority interest in the precision medicine and …

GSK

Glaxo’s Dovato Wins EU Nod, RA Candidate Enters Phase III - July 4, 2019 - Zacks.com | 7/4/2019

GlaxoSmithKline plc ’s ( GSK - Free Report ) HIV subsidiary, ViiV Healthcare, announced that the European Commission has granted a marketing authorization to Dovato, its once-daily, single-tablet two-drug HIV regimen. The approval in the … data from the phase II BAROQUE study, which showed striking clinical improvements in patients treated with otilimab. Zacks Rank Glaxo currently carries a Zacks Rank 3 (Hold). You can see the complete list of today’s …

ViiV Healthcare

Glaxo’s Dovato Wins EU Nod, RA Candidate Enters Phase III - July 4, 2019 - Zacks.com | 7/4/2019

GlaxoSmithKline plc ’s ( GSK - Free Report ) HIV subsidiary, ViiV Healthcare, announced that the European Commission has granted a marketing authorization to Dovato, its once-daily, single-tablet two-drug HIV regimen. The approval in the … data from the phase II BAROQUE study, which showed striking clinical improvements in patients treated with otilimab. Zacks Rank Glaxo currently carries a Zacks Rank 3 (Hold). You can see the complete list of today’s …

Celgene

–Fedratinib demonstrated clinical improvement in | 1/8/2018

Fedratinib demonstrated clinical improvement in a phase III trial with treatment-naive myelofibrosis patients and in a phase II trial with myelofibrosis patients resistant or intolerant to ruxolitinib \n –A New Drug Application (NDA) submission for fedratinib in myelofibrosis is planned for mid-2018 \n Celgene Corporation ( NASDAQ:CELG ) and Impact Biomedicines today \n announced the signing of a definitive agreement in which Celgene will \n acquire Impact Biomedicines, which …

Morgan Stanley

Edited Transcript of INSM earnings conference call or presentation 30-Apr-20 12:30pm GMT | Yahoo News | 6/6/2020

… CEO & Chairman Conference Call Participants Adam Anderson Walsh Stifel, Nicolaus & Company, Incorporated, Research Division - MD & Senior Analyst Connor McGuinness Meehan Morgan Stanley, Research Division - Research Associate Graig Suvannavejh Goldman Sachs Group Inc., Research Division - Executive … on top of standard of care. The primary endpoint is clinical improvement on a 7-point ordinal scale as defined by the World Health Organization. Patients will be treated for up to 28 days with …

Live updates on COVID-19: April 1-15 | Modern Healthcare | 5/5/2020

… every shift. Several local news outlets also believe some states are undercounting the number of people succumbing to the disease. Morgan Stanley’s estimates on outbreak recovery Morgan Stanley: “While we understand the desire for optimism … remdesivir on patients hospitalized for severe COVID-19 resulted in clinical improvement 36 of 53, or 68%, of patients, according to an article in the New England Journal of Medicine. The Gilead Sciences-funded trial …

Goldman Sachs

Edited Transcript of INSM earnings conference call or presentation 30-Apr-20 12:30pm GMT | Yahoo News | 6/6/2020

… Stifel, Nicolaus & Company, Incorporated, Research Division - MD & Senior Analyst Connor McGuinness Meehan Morgan Stanley, Research Division - Research Associate Graig Suvannavejh Goldman Sachs Group Inc., Research Division - Executive Director & Senior Equity Research Analyst Joseph Patrick Schwartz … on top of standard of care. The primary endpoint is clinical improvement on a 7-point ordinal scale as defined by the World Health Organization. Patients will be treated for up to 28 days with …

Atara Biotherapeutics’ (ATRA) CEO Pascal Touchon on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/9/2019

… Rama – JPMorgan John Newman – Canaccord Salim Syed – Mizuho Securities Phil Nadeau – Cowen and Company Tony Butler – Roth Capital Salveen Richter – Goldman Sachs Ben Burnett – Stifel Maury Raycroft – Jefferies Operator Ladies and gentlemen, thank you for … tolerated safety profile and at least 50% of patients experiencing clinical improvement based on the multi-scale assessment defined at ECTRIMS with improving patient coming from more than one clinical study site. Recognizing these are …

Merrill Lynch

Shockwave Medical Inc (SWAV) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/11/2019

… Ordinarily when a medical device is being assessed for an add-on payment CMS looks at 3 criteria: newness substantial clinical improvement to alternative treatments and costs. However ,for a device that has been granted … Robert Hopkins with Bank of America. Kyle Andrew Pezzi – BofA Merrill Lynch – Analsyt This is Kyle Pezzi on for Bob. Just a quick question to kind of follow up to David. Obviously earlier this month …

Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/15/2019

… ET Company Participants Bryan Giraudo - CFO Sheila Gujrathi - Co-Founder and CEO Conference Call Participants Ying Huang - Bank of America/Merrill Lynch Joseph Schwartz - SVB Leerink Josh Schimmer - Evercore Operator Good morning, and welcome to … the induction timeframe of where we can start seeing some clinical improvement. So a lot of data will be coming out of that Phase 1b trial. So again pretty exciting studies from our perspective and …

William Blair

CELYAD SA/ADR’s (CYAD) Buy Rating Reiterated at William Blair - Ticker Report | 8/26/2019

William Blair reaffirmed their buy rating on shares of CELYAD SA/ADR (NASDAQ:CYAD) in a research note published on Friday, AnalystRatings.com reports. “We believe that the data readouts in the second half of the year will shed light into the clinical improvements with the Optimab process, allogeneic platform, and the impact of the preconditioning regimen at potentially clinically relevant doses with an eye toward selecting a Phase II (potentially …

Premier, Inc. (PINC) CEO Susan DeVore on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/12/2019

… Alkire - President & COO Craig McKasson - CFO, CAO, Senior VP & Treasurer Conference Call Participants Michael Cherny - Bank of America Ryan Daniels - William Blair Stephanie Demko - Citi Sean Dodge - Jefferies Kevin Caliendo - UBS Charles Rhyee - Cowen Sean … and leverage enterprise analytics to drive improved financial, operational and clinical improvement. In addition, we’re encouraged by recent federal government health policy announcements, as Premier continues to lead and support health systems in their transition …

Hearst Health Ventures

With Quality a Top Priority, Ardent Health Services Expands Its Use of Zynx Health’s Knowledge Analyzer | PR Newswire | 7/9/2019

LOS ANGELES Zynx Health ™, market leader in providing evidence- and experience-based clinical improvement solutions since 1996, announced today that long-time client Ardent Health Services is expanding its agreement for use of Zynx’s Knowledge … Homecare Homebase, MHK (formerly MedHOK—Medical House of Knowledge) and Hearst Health Ventures ( www.hearsthealth.com ). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. Follow Hearst Health on Twitter @HearstHealth …

Zynx Health to Host Webinar: “Zynx FHIR API: Your Shortcut to App Excellence” | PR Newswire | 11/2/2017

… by 08:04 ET Share this article LOS ANGELES , Nov. Zynx Health ™, a market leader in providing evidence- and experience-based clinical improvement solutions, today announced it will host a live, complimentary webinar entitled, “ Zynx FHIR … Databank), Zynx Health, MCG, Homecare Homebase, MedHOK, Hearst Health International, Hearst Health Ventures and the Hearst Health Innovation Lab ( www.hearsthealth.com ). The mission of the Hearst Health network is to help guide the most important care …

Northwell Health

Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus | BMJ | 6/8/2020

Table 3 NYP/CUMC and Northwell Health adult inpatients with PML codes One Northwell Health patient with ICD codes for both SLE and PML had a presentation consistent with CNS lupus and not PML with CSF negative for JC virus, and clinical improvement with increased immunosuppression. Of 2046 patients, 979 were being treated with glucocorticoids, 260 with mycophenolate mofetil, 85 with intravenous cyclophosphamide, 40 with rituximab, 70 with azathioprine, 616 …

Northwell memo calls for rationing ventilators to ‘patients most likely to benefit’ | Politico | 4/3/2020

Northwell Health wrote in a six-page memo titled “Public Health Emergency: Life Sustaining Treatment Decisions for all Patients” and distributed to medical staff. Advertisement The guidance, which was obtained by POLITICO, recommends that medical teams reevaluate patients with advanced illnesses who are breathing through a ventilator for three days if they show no “no clinical improvement.” At that point, the team should consult palliative care specialists to discuss whether …

Medical Center

Balt Receives IDE Approval From the FDA to Begin the STEM Trial | Business Wire | 5/15/2020

… Semmes-Murphey Neurologic and Spine Institute and University of Tennessee Health Sciences Center) and Dr. David Fiorella (Stony Brook University Medical Center) have worked diligently to design a meaningful prospective, randomized, controlled, multi-center trial … on to state, “We have seen some dramatic radiological and clinical improvement using liquid embolic agents to treat patients with cSDH, both as an adjunct to surgical treatment and as a stand-alone therapy. We …

Balt Receives IDE Approval From the FDA to Begin the STEM Trial | Business Wire | 5/15/2020

… Semmes-Murphey Neurologic and Spine Institute and University of Tennessee Health Sciences Center) and Dr. David Fiorella (Stony Brook University Medical Center) have worked diligently to design a meaningful prospective, randomized, controlled, multi-center trial … on to state, “We have seen some dramatic radiological and clinical improvement using liquid embolic agents to treat patients with cSDH, both as an adjunct to surgical treatment and as a stand-alone therapy. We …

University Medical Center

Balt Receives IDE Approval From the FDA to Begin the STEM Trial | Business Wire | 5/15/2020

… Arthur (Semmes-Murphey Neurologic and Spine Institute and University of Tennessee Health Sciences Center) and Dr. David Fiorella (Stony Brook University Medical Center) have worked diligently to design a meaningful prospective, randomized, controlled, multi-center … on to state, “We have seen some dramatic radiological and clinical improvement using liquid embolic agents to treat patients with cSDH, both as an adjunct to surgical treatment and as a stand-alone therapy. We …

Balt Receives IDE Approval From the FDA to Begin the STEM Trial | Business Wire | 5/15/2020

… Arthur (Semmes-Murphey Neurologic and Spine Institute and University of Tennessee Health Sciences Center) and Dr. David Fiorella (Stony Brook University Medical Center) have worked diligently to design a meaningful prospective, randomized, controlled, multi-center … on to state, “We have seen some dramatic radiological and clinical improvement using liquid embolic agents to treat patients with cSDH, both as an adjunct to surgical treatment and as a stand-alone therapy. We …

Children's Hospital

MDmetrix Helps Eliminate Opioids for Most Pediatric Outpatient Surgeries | PR Newswire | 4/28/2020

… company, announced today that its artificial intelligence (AI)-driven technology was a pivotal component in a joint initiative with Seattle Children’s Hospital at its Bellevue Clinic and Surgery Center (BCSC) to develop the nation’s first … cycle, which is the standard methodology for the development of clinical improvements using real-world data. “Using MDmetrix, we have been able to accelerate our PDSA-driven improvement work at a pace far beyond traditional …

Using Automated Risk Scoring to Spot Pediatric Patient Deterioration | HealthIT Analytics | 4/16/2020

… patterns, and poorer overall health, and understanding where the greatest risks lie can help providers focus their efforts. Renuka Mehta, Children’s Hospital of Georgia Source: Xtelligent Healthcare Media At Children’s Hospital of Georgia, part of … so it’s been a positive change,” Mehta said. “We’ve seen clinical improvement, and overall improvements in patient care. It’s saved time related to documentation, and our rapid response teams can act much earlier.” Tagged …

Cedars-Sinai Medical Center

Two studies have some good news and bad news for potential coronavirus treatments | Vox | 4/12/2020

… that is, patients were given the unapproved drug because no other options were available. According to the report, doctors observed clinical improvement in 36 of the 53 patients; eight got worse, and seven died. Doctors … author of the analysis and director of hospital epidemiology at Cedars-Sinai Medical Center in Los Angeles, in a statement from Gilead. “We look forward to the results of controlled clinical trials to potentially validate …

Chief Artificial Disc Replacement Innovator Dr. Todd Lanman Selected as Los Angeles’ Premier Provider of New FDA-Approved Anatomical M6 Cervical Disc Device | PRWeb | 4/23/2019

… disc. At the 24-month mark, clinical patient outcomes have shown the M6-C device to demonstrate a statistically superior clinical improvement in the Neck Disability Index in 90.5 percent of patients, and nearly the … practice in the heart of Beverly Hills is affiliated with Cedars-Sinai Medical Center and UCLA Medical Center. Lanman has published nearly a dozen peer-reviewed articles, as well as book chapters on topics relating …

Harvard Medical School

Biologics Alliance™ Initiates Collaboration Within Orthopaedics Community | PR Newswire | 11/25/2019

… into question the ability of treatments such as oral medications, injection therapies, physical therapy, arthroscopy and arthroplasty to provide significant clinical improvement to patients with osteoarthritis (OA), the most common condition evaluated and treated by … Director, Cartilage Repair Center at Brigham and Women’s Hospital at Harvard Medical School Bert Mandelbaum , M.D., (Co-Chair of the Alliance) , Co-Chair, Medical Affairs Cedars Sinai Kerlan Jobe Institute, Co-Director, Sports Medicine Cedars …

Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug Development Platform | Business Wire | 11/21/2019

… Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School, Mario Suvà M.D., Ph.D ., an Associate Professor in the Department of Pathology … tumors, thereby advancing discoveries directly from the bench into meaningful clinical improvements. Our focus on human data allows us to start with and stay closer to the biology that is most relevant in patients and …

Hospital for Special Surgery

Biologics Alliance™ Initiates Collaboration Within Orthopaedics Community | PR Newswire | 11/25/2019

… into question the ability of treatments such as oral medications, injection therapies, physical therapy, arthroscopy and arthroplasty to provide significant clinical improvement to patients with osteoarthritis (OA), the most common condition evaluated and treated by … Informatics at Osaka University Scott Rodeo, M.D. , Professor, Orthopedic Surgery, Hospital for Special Surgery/Weill Cornell Medical College; Vice Chair of Orthopaedic Research, Co-Chief Emeritus, Sports Medicine Institute, Hospital for Special Surgery; Head Team …

Biologics Alliance(TM) Initiates Collaboration Within Orthopaedics Community | 11/25/2019

… into question the ability of treatments such as oral medications, injection therapies, physical therapy, arthroscopy and arthroplasty to provide significant clinical improvement to patients with osteoarthritis (OA), the most common condition evaluated and treated by … Informatics at Osaka University Scott Rodeo, M.D. , Professor, Orthopedic Surgery, Hospital for Special Surgery/Weill Cornell Medical College; Vice Chair of Orthopaedic Research, Co-Chief Emeritus, Sports Medicine Institute, Hospital for Special Surgery; Head Team …

Patrik Jonsson

Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients | PR Newswire | 6/15/2020

clinical improvement at different time points, time to recovery, duration of hospitalization, number of ventilator-free days and mortality over a 28-day period. “Lilly is committed to fighting this global pandemic, and this includes testing whether existing medicines including baricitinib could help treat the complications of COVID-19 in patients,” said Patrik Jonsson , Lilly senior vice president and president of Lilly Bio-Medicines. “This randomized controlled study is an …

Anthony Fauci

Remdesivir in the plague year: “Observations of the most remarkable occurences” | BMJ | 6/10/2020

… associated with statistically significant clinical benefits in the treatment of severe covid-19. However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.” [ 2] On the same … AP News proclaimed the results “A 1 st ” and quoted Anthony Fauci of the National Institutes of Health saying that “What it has proven is that a drug can block this virus,” that “This will …

Merdad Parsey

More evidence remdesivir helps some coronavirus patients | Philly Tribune | 6/3/2020

… today, we now have three randomized, controlled clinical trials demonstrating that remdesivir improved clinical outcomes by several different measures,” Dr. Merdad Parsey, chief medical officer for Gilead Sciences, said in a company statement . Gilead originally … five-day course of remdesivir were more likely to have clinical improvement after 11 days compared to those who received traditional standard of care alone, Gilead said. However, while patients who received a 10-day …

Deena Beasley

Gilead study shows shorter 5-day course of remdesivir works as well as 10-day one | Yahoo News | 5/29/2020

FILE PHOTO: A vial of redesivir More By Deena Beasley (Reuters) - Gilead Sciences Inc, which has suggested that a shorter treatment duration could extend limited supplies of its drug remdesivir, on Wednesday published results of … 5 days and 54% treated for 10 days showed some clinical improvement. At the 14-day mark, 8% of patients in the 5-day group and 11% of patients in the 10-day group had …

Levi Garraway

Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia | Globe Newswire | 5/28/2020

… becomes available in these unprecedented times, it is more important than ever to work together to fight this disease,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Based … mortality, mechanical ventilation, clinical status at day 14, time to clinical improvement, and time to discharge. About Actemra/RoActemra Actemra/RoActemra was the first approved anti-IL-6 receptor biologic available in both intravenous (IV …

Umer Raffat

Detailed COVID-19 data for Gilead’s remdesivir are finally here, confirming its benefits and limitations | FiercePharma | 5/26/2020

… said. RELATED: Gilead to start selling remdesivir in coming weeks, expects ‘multi-year commercial opportunity’ Still, as Evercore ISI analyst Umer Raffat sees it, the NEJM paper is missing one key data set. “The single … due to low enrollment, researchers only found a numerically faster clinical improvement with remdesivir use compared with placebo in patients who started treatment with symptom duration of 10 days or less. Gilead itself is running …

Nesim Bildirici

AMC Health Expands Partnership with Gallagher Home Health Services to Utilize Telehealth Monitoring Solutions to Help Assess, Monitor and Triage COVID Patients At-Home | PR Newswire | 5/4/2020

… one-size-fits-all approach – it’s about meeting the needs of our clients when and where they want it,” said Nesim Bildirici , CEO of AMC Health. AMC’s telehealth capabilities serve hospitals, health plans, and Veterans … a single connection. AMC Health’s peer-reviewed published studies highlight clinical improvements for conditions like heart failure, diabetes, COPD and hypertension, resulting in reductions in hospital admissions, and solid financial return on investment. For more …

Matthew Herper

Gilead: Critical study of Covid-19 drug shows patients respond to treatment | STAT | 4/29/2020

Biotech Critical study of Gilead’s Covid-19 drug shows patients are responding to treatment, NIH says By Matthew Herper @matthewherper and Adam Feuerstein @adamfeuerstein April 29, 2020 A vial of remdesivir ULRICH PERREY/POOL/AFP … with severe Covid-19. This study showed similar rates of clinical improvement in patients treated with a five-day and 10-day course of remdesivir, the company said. “Unlike traditional drug development, we are attempting …

Adam Feuerstein

Gilead: Critical study of Covid-19 drug shows patients respond to treatment | STAT | 4/29/2020

… Critical study of Gilead’s Covid-19 drug shows patients are responding to treatment, NIH says By Matthew Herper @matthewherper and Adam Feuerstein @adamfeuerstein April 29, 2020 A vial of remdesivir ULRICH PERREY/POOL/AFP via … with severe Covid-19. This study showed similar rates of clinical improvement in patients treated with a five-day and 10-day course of remdesivir, the company said. “Unlike traditional drug development, we are attempting …

Andy Boral

Blueprint Medicines Announces Part 1 Results from PIONEER Trial Showing Broad Activity of Avapritinib Across Measures of Mast Cell Burden, Clinical Outcomes and Quality of Life in Indolent Systemic Mastocytosis | PR Newswire | 3/16/2020

… announced updated results from the Phase 2 PIONEER trial of avapritinib in patients with indolent systemic mastocytosis (SM) showing significant clinical improvements versus placebo. In Part 1 of the PIONEER trial, patients treated with avapritinib … with the goal of delivering transformative benefit to patients,” said Andy Boral , M.D., Ph.D., Chief Medical Officer at Blueprint Medicines. “In indolent SM, these placebo-controlled data are the first to show consistent clinical activity …

Bruce Pat

CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140) | Globe Newswire | 3/9/2020

… as a therapy for patients who experience respiratory complications as a result of contracting the coronavirus disease 2019 (COVID-19). Bruce Patterson M.D., CEO of IncellDX and advisor to CytoDyn explains: “Leronlimab inhibits migration of … in subjects with coronavirus 2019 infection. Primary Outcome (Endpoint) Measure: Clinical Improvement based on change in total symptom score (for fever, myalgia, dyspnea and cough)Note: The total score per patient ranges from 0 to …

Anupam Rama

Atara Biotherapeutics’ (ATRA) CEO Pascal Touchon on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/9/2019

… Investor Relations and Corporate Communications Pascal Touchon – President and Chief Executive Officer AJ Joshi – Chief Medical Officer Conference Call Participants Anupam Rama – JPMorgan John Newman – Canaccord Salim Syed – Mizuho Securities Phil Nadeau – Cowen and Company … tolerated safety profile and at least 50% of patients experiencing clinical improvement based on the multi-scale assessment defined at ECTRIMS with improving patient coming from more than one clinical study site. Recognizing these are …

Craig Fraser

Windtree Therapeutics Provides Business Update – Company Announcement - FT.com | Financial Times | 10/25/2019

… our data analysis, gained increased regulatory clarity and evolved our development strategies for the next stages of program execution,” commented Craig Fraser , President and Chief Executive Officer. “We are excited about the opportunities before us … dose group), suggesting that istaroxime could potentially contribute to the clinical improvement of patients in cardiogenic shock due to heart failure. Because of the unmet need, there may be opportunities for an enhanced regulatory pathway …

Adam Grossman

ADMA Biologics Named Company of the Year by BioFlorida | Globe Newswire | 10/22/2019

… BioFlorida and to be recognized for the recent achievements at our Boca Raton, Florida biologics manufacturing and laboratory campus,” stated Adam Grossman, President and Chief Executive Officer. “Over the past year, we were granted two … plasma-based biologics products and product candidates to provide meaningful clinical improvement for patients living with Primary Immune Deficiency Disease or other indications. Actual events or results may differ materially from those described in this …

Mark Roth

Orchard Therapeutics plc (ORTX) CEO Mark Rothera on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/28/2019

… NASDAQ: ORTX ) Q1 2019 Earnings Conference Call May 28, 2019 8:00 AM ET Company Participants Renee Leck - Director, Investor Relations Mark Rothera - President, Chief Executive Officer Bobby Gaspar - Chief Scientific Officer Frank Thomas - Chief Financial … clouding and upper airway congestion, and has resumed growth, suggesting clinical improvement. We look forward to updating you on this proof of concept trial. We expect to complete enrolment of up to 8 patients in …

Chaim Lebovits

BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update | Globe Newswire | 5/11/2019

… our Phase 2 trial of NurOwn ® in Progressive MS (Multiple Sclerosis) in several of the preeminent U.S. medical institutions,” commented Chaim Lebovits, President and Chief Executive Officer of BrainStorm Cell Therapeutics. He added, “We anticipate … production by NurOwn ® and further correlate cerebrospinal fluid biomarkers with clinical improvement in the completed Phase 2 ALS study. These findings contribute to our overall understanding of the mechanism of action of NurOwn ® and provide …

Ralph Kern

BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update | Globe Newswire | 5/11/2019

… study of repeated intrathecal administration of autologous MSC-NTF cells in participants with progressive MS. On January 11, 2019, Dr. Ralph Kern, Chief Operating Officer and Chief Medical Officer, presented an update on the Phase … production by NurOwn ® and further correlate cerebrospinal fluid biomarkers with clinical improvement in the completed Phase 2 ALS study. These findings contribute to our overall understanding of the mechanism of action of NurOwn ® and provide …

David Evans

Guardion’s Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Function (CSF) vs AREDS 2 | Markets Insider | Business Insider | 5/9/2019

David Evans, Ph.D., Guardion’s Chief Science Officer, commenting on the results of the study, stated, “We are pleased to present for the first-time clinical data showing the beneficial effects of our liquid lipid-based formula Lumega-Z as compared to the AREDS 2 softgel supplement. This data supports numerous clinical reports that we have showing substantial clinical improvements in patients who switched from the AREDS 2 softgel to Lumega …

State of Washington

Coronavirus tracker: U.S. calls dibs on remdesivir supplies; Sinopharm doubles shot capacity with new Wuhan plant | FiercePharma | 7/1/2020

… people for COVID-19 at the same time in what’s known as pool testing, NIAID director Anthony Fauci told the Washington Post on Friday. A group of patients would be given a single coronavirus test … of remdesivir were 65% more likely to show signs of clinical improvement compared with patients who received standard care, the company said. Story Could COVID-19 be a vascular disease? The Lancet explored the idea …

CytoDyn Reached Its Enrollment Target for Phase 2 COVID-19 Trial for Mild to Moderate Indication – Primary End Point Announcement Is Next | 6/12/2020

VANCOUVER, Washington, June 11, 2020 (GLOBE NEWSWIRE) – CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced … Mild to Moderate COVID-19.” This Phase 2 trial evaluates clinical improvement of several symptoms over a 14-day period, including changes in multiple clinical baseline metrics after days 3, 7 and 14. The Company …

New York, New York

Satisfactory Progress Reports for MitraClip Alternatives | 6/25/2020

… mild in all implanted patients at 30 days (83.3% had no MR). Symptoms improved from 64.3% of patients being in New York Heart Association (NYHA) class III or worse at baseline to 81.8% left with … and 92.0% had grade 4+ MR. Muller highlighted the sustained clinical improvement observed in terms of NYHA classification (81.7% in class I/II at 2 years) and a 19-point improvement on the Kansas City …

Complete List of Companies Developing a Coronavirus Vaccine & Treatment | 6/22/2020

… of Remdesivir in Patients With Moderate COVID-19. Study Demonstrates 5-Day Treatment Course of Remdesivir Resulted in Significantly Greater Clinical Improvement Versus Treatment with Standard of Care Alone. Data Add to Body of Evidence … is an American high-technology company based in Stony Brook, New York that develops and employs unique technologies for the purpose of preventing counterfeiting. About : EVVIVAX is a spin-off of Takis Biotech, a company …

York, Pennsylvania

Satisfactory Progress Reports for MitraClip Alternatives | 6/25/2020

… in all implanted patients at 30 days (83.3% had no MR). Symptoms improved from 64.3% of patients being in New York Heart Association (NYHA) class III or worse at baseline to 81.8% left with NYHA … and 92.0% had grade 4+ MR. Muller highlighted the sustained clinical improvement observed in terms of NYHA classification (81.7% in class I/II at 2 years) and a 19-point improvement on the Kansas City …

Complete List of Companies Developing a Coronavirus Vaccine & Treatment | 6/22/2020

… of Remdesivir in Patients With Moderate COVID-19. Study Demonstrates 5-Day Treatment Course of Remdesivir Resulted in Significantly Greater Clinical Improvement Versus Treatment with Standard of Care Alone. Data Add to Body of Evidence … an American high-technology company based in Stony Brook, New York that develops and employs unique technologies for the purpose of preventing counterfeiting. About : EVVIVAX is a spin-off of Takis Biotech, a company developing …

State of New York

Satisfactory Progress Reports for MitraClip Alternatives | 6/25/2020

… mild in all implanted patients at 30 days (83.3% had no MR). Symptoms improved from 64.3% of patients being in New York Heart Association (NYHA) class III or worse at baseline to 81.8% left with … and 92.0% had grade 4+ MR. Muller highlighted the sustained clinical improvement observed in terms of NYHA classification (81.7% in class I/II at 2 years) and a 19-point improvement on the Kansas City …

Complete List of Companies Developing a Coronavirus Vaccine & Treatment | 6/22/2020

… of Remdesivir in Patients With Moderate COVID-19. Study Demonstrates 5-Day Treatment Course of Remdesivir Resulted in Significantly Greater Clinical Improvement Versus Treatment with Standard of Care Alone. Data Add to Body of Evidence … is an American high-technology company based in Stony Brook, New York that develops and employs unique technologies for the purpose of preventing counterfeiting. About : EVVIVAX is a spin-off of Takis Biotech, a company …

State of California

COVID-19 Treatments — Coronavirus Today | 6/30/2020

… immune modulator for the treatment of outpatients with early COVID-19 disease. June 26, 2020 - The governing Board of the California Institute for Regenerative Medicine (CIRM) awarded $750,000 to Dr. Xiaokui Zhang at Celularity to … to standard treatment did not significantly improve the time to clinical improvement within 28 days, although the trial was terminated early and may have been underpowered to detect a clinically important difference, reported a study …

3 “Strong Buy” Coronavirus Stocks With Massive Upside Potential | Yahoo News | 6/29/2020

COVID-19 might not be going anywhere anytime soon. Last week, Florida, Texas, California and Arizona all reported that the daily rate of new infections had spiked. Heightened fears of a second wave and the … pneumonia and hyperinflammation, patients given KNSA’s candidate saw a significant clinical improvement. Highlighting the details of the study, JMP analyst Liisa Bayko pointed out that each patient was given medical treatment hydroxychloroquine, azithromycin and lopinavir …

State of Florida

3 “Strong Buy” Coronavirus Stocks With Massive Upside Potential | Yahoo News | 6/29/2020

COVID-19 might not be going anywhere anytime soon. Last week, Florida, Texas, California and Arizona all reported that the daily rate of new infections had spiked. Heightened fears of a second wave and the … pneumonia and hyperinflammation, patients given KNSA’s candidate saw a significant clinical improvement. Highlighting the details of the study, JMP analyst Liisa Bayko pointed out that each patient was given medical treatment hydroxychloroquine, azithromycin and lopinavir …

3 “Strong Buy” Coronavirus Stocks With Massive Upside Potential | 6/29/2020

COVID-19 might not be going anywhere anytime soon. Last week, Florida, Texas, California and Arizona all reported that the daily rate of new infections had spiked. Heightened fears of a second wave and the … pneumonia and hyperinflammation, patients given KNSA’s candidate saw a significant clinical improvement. Highlighting the details of the study, JMP analyst Liisa Bayko pointed out that each patient was given medical treatment hydroxychloroquine, azithromycin and lopinavir …

State of Arizona

3 “Strong Buy” Coronavirus Stocks With Massive Upside Potential | Yahoo News | 6/29/2020

COVID-19 might not be going anywhere anytime soon. Last week, Florida, Texas, California and Arizona all reported that the daily rate of new infections had spiked. Heightened fears of a second wave and the … pneumonia and hyperinflammation, patients given KNSA’s candidate saw a significant clinical improvement. Highlighting the details of the study, JMP analyst Liisa Bayko pointed out that each patient was given medical treatment hydroxychloroquine, azithromycin and lopinavir …

3 “Strong Buy” Coronavirus Stocks With Massive Upside Potential | 6/29/2020

COVID-19 might not be going anywhere anytime soon. Last week, Florida, Texas, California and Arizona all reported that the daily rate of new infections had spiked. Heightened fears of a second wave and the … pneumonia and hyperinflammation, patients given KNSA’s candidate saw a significant clinical improvement. Highlighting the details of the study, JMP analyst Liisa Bayko pointed out that each patient was given medical treatment hydroxychloroquine, azithromycin and lopinavir …

Chicago, Illinois

More positive results for antiviral drug remdesivir in battle against COVID-19 | Chicago Tribune | 6/3/2020

Chicago Tribune Jun 02, 2020 6:57 PM Dr. Gregory Huhn, an infectious disease physician at Stroger Hospital, poses for a portrait on May 4, 2020, outside of Cook County Health in Chicago. Huhn headed up … this newsletter. See all newsletters. “Now with solid evidence of clinical improvement for both severe illness and moderate illness … I would believe that these data would move the FDA for licensure consideration,” Huhn said. The …

Live updates on COVID-19: April 1-15 | Modern Healthcare | 5/5/2020

… 8:45 PM CT on 4/10/2020 A compassionate-use trial of remdesivir on patients hospitalized for severe COVID-19 resulted in clinical improvement 36 of 53, or 68%, of patients, according to an article in the … not near leveling off 4:49 PM CT on 4/10/2020 ( Crain’s Chicago Business ) If Italy’s COVID journey is any indication of the path we’re taking, then we’re starting to see the light at the end of …

Boston, Massachusetts

Association Between Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy–Related Inflammation | 6/22/2020

… Amyloid Angiopathy–Related Inflammation 1 J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston 2 Neuropathology Service, C. S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Harvard Medical … of 48 patients with cerebral amyloid angiopathy–related inflammation, both clinical improvement and radiographic improvement were more likely to occur in individuals treated with an immunosuppressive agent than in untreated individuals; recurrence was also significantly …

726 IMPACT OF LUMEN-APPOSING METAL STENTS ON THE LONG-TERM MANAGEMENT OF DISCONNECTED PANCREATIC DUCT SYNDROME | 6/1/2020

Boston Scientific, USA). After confirmation of clinical improvement and resolution of the fluid collection on follow-up CT/MRI at 3 to 4 weeks, the LAMS were removed. In patients with DPDS, when feasible, the LAMS were replaced with 7Fr double pigtail plastic stents to facilitate the drainage of the disconnected pancreatic segment and to prevent PFC recurrence. All patients were prospectively followed for a minimum duration of 6 months …

State of Massachusetts

Complete List of Companies Developing a Coronavirus Vaccine & Treatment | 6/22/2020

… coronavirus vaccine & treatment. At least four companies have already tested their experimental drugs on animals. Moderna, a biotech company in Massachusetts, has already shipped its first batches of the COVID-19 vaccine to the US … 5-Day Treatment Course of Remdesivir Resulted in Significantly Greater Clinical Improvement Versus Treatment with Standard of Care Alone. Data Add to Body of Evidence from Prior Studies Demonstrating Benefit of Remdesivir in Hospitalized Patients …

Association Between Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy–Related Inflammation | 6/22/2020

… Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy–Related Inflammation 1 J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston 2 Neuropathology Service, C. S. Kubik Laboratory for … of 48 patients with cerebral amyloid angiopathy–related inflammation, both clinical improvement and radiographic improvement were more likely to occur in individuals treated with an immunosuppressive agent than in untreated individuals; recurrence was also significantly …